The effects of continuous renal replacement on anti-infective therapy in the critically ill

Journal of Pharmacy Practice

Volumn 18, Issue 2, 2005, Pages 109-117

  Kubin, Christine ^a   Dzierba, Amy ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Antimicrobials; Continuous renal replacement therapy; Drug dosing; Renal failure

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; NAFCILLIN; OFLOXACIN; OXACILLIN; PENICILLIN G; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG EFFECT; GRAM NEGATIVE INFECTION; HEALTH CARE UTILIZATION; HEMODIALYSIS; HEMODYNAMICS; HUMAN; KIDNEY TRANSPLANTATION; METABOLIC REGULATION; REVIEW; RISK; SIDE EFFECT;

EID: 16344379008     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190004273596     Document Type: Review

References (61)

1. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996;275:1489-1494.
2. de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000;26:915-921.
3. Liano F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int Suppl. 1998;66:S16-24.
4. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med. 1996;334:1448-1460.
5. Breen D, Bihari D. Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int Suppl. 1998;66:S25-33.
6. Meyer MM. Renal replacement therapies. Crit Care Clin. 2000;16:29-58.
7. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998;32:362-375.
8. Ronco C, Bellomo R. Continuous renal replacement therapy: evolution in technology and current nomenclature. Kidney Int Suppl. 1998;66:S160-164.
9. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand. 2001;45:929-934.
10. Bugge JF. Influence of renal replacement therapy on pharmacokinetics in critically ill patients. Best Pract Res Clin Anaesthesiol. 2004;18:175-187.
11. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 1995;21:612-620.
12. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Phaimacol 1996;36:1114-1119.
13. Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl. 1999;72:S24-28.
14. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin Pharmacokinet. 1993;24:362-379.
15. Vos MC, Vincent HH, Yzerman EPF, Vogel M. Drug clearance by continuous haemodiafiltration: results with the AN-69 capillary haemofilter and recommended dose adjustments for seven antibiotics. Drug Invest. 1994;7:315-322.
16. Kronfol NO, Lau AH, Barakat MM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. ASAIO Trans. 1987;33:300-303.
17. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest. 1999;115:19S-23S.
18. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589-596.
19. Golper TA, Marx MA. Drug dosing adjustments during continuous renal replacement therapies. Kidney Int Suppl. 1998;66:S165-168.
20. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2001;48:881-885.
21. van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med. 1997;23:873-877.
22. Keller E, Bohler J, Busse-Grawitz A, Reetze-Bonorden P, Krumme B, Schollmeyer P. Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients. Clin Nephrol. 1995;43(suppl 1):S20-23.
23. Bressolle F, Kinowski JM, de la Coussaye JE, Wynn N, Eledjam JJ, Galtier M. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994;26:457-471.
24. Weiss LG, Cars O, Danielson BG, Grahnen A, Wikstrom B. Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol. 1988;30:282-286.
25. Garcia MJ, Dominguez-Gil A, Tabernero JM, Diaz Molina M. Pharmacokinetics of cefoxitin during haemofiltration. Eur J Clin Pharmacol. 1983;25:395-398.
26. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicmb Agents Chemother. 2000;44:1639-1644.
27. Traunmuller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicmb Chemother. 2002;49:129-134.
28. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2001;45:3148-3155.
29. Allaouchiche B, Breilh D, Jaumain H, Gaillard B, Renard S, Saux MC. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 1997;41:2424-2427.
30. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989;24(suppl A):311-320.
31. Robatel C, Decosterd LA, Biollaz J, Eckert P, Schaller MD, Buclin T. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol. 2003;43:1329-1340.
32. Ververs TF, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med. 2000;28:3412-3416.
33. Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous venovenous hemofiltration. Chemotherapy. 2003;49:280-286.
34. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000;28:632-637.
35. Tegeder I, Bremer F, Oelkers R, et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1997;41:2640-2645.
36. Przechera M, Bengel D, Risler T. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration. Contrib Nephrol. 1991;93:131-134.
37. Thalhammer F. Meropenem and continuous renal replacement. Crit Care Med. 2001;29:1653-1654.
38. Kropp H, Sundelof JG, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982;22:62-70.
39. Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ASAIO J. 1997;43:84-88.
40. Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis. 1993;21:172-179.
41. Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med. 1990;18:675-676.
42. Zarowitz BJ, Anandan JV, Dumler F, Jayashankar J, Levin N. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol. 1986;26:686-689.
43. Thomson AH, Grant AC, Rodger RS, Hughes RL. Gentamicin and vancomycin removal by continuous venovenous hemofiltration. D1CP. 1991;25:127-129.
44. Ernest D, Cutler DJ. Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med. 1992;20:586-589.
45. Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med. 1999;25:1100-1104.
46. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004;58:259-268.
47. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy. 1990;10:141S-145S.
48. Muhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol. 2000;56:671-678.
49. Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother. 1997;40:695-700.
50. Robatel C, Rusca M, Padoin C, Marchetti O, Liaudet L, Buclin T. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CWHDF) in a single patient. J Antimicrob Chemother. 2004;54:269-270.
51. Coronel B, Persat F, Dorez D, Moskovtchenko JF, Peins MA, Mercatello A. Itraconazole concentrations during continuous haemodiafiltration. J Antimicrob Chemother. 1994;34:448-449.
52. Bellmann R, Egger P, Djanani A, Wiedermann CJ. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int J Antimicrob Agents. 2004;23:80-83.
53. Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother. 2003;51:671-681.
54. Khajehdehi P, Jamal JA, Bastani B. Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. Clin Nephrol. 2000;54:351-355.
55. Boulieu R, Bastien O, Bleyzac N. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit. 1993;15:105-107.
56. Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y. Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Crit Care Med. 1998;26:184-187.
57. Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J. 2000;19:95-104.
58. Beghi G, Berni F, Carratu L, et al. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother. 1995;7:146-152.
59. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis. 1998;27:730-738.
60. Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis. 1998;27:722-729.
61. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125-129.